Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers
DOI10.1111/BIOM.12437zbMATH Open1419.62491OpenAlexW2128864973WikidataQ50772013 ScholiaQ50772013MaRDI QIDQ5739265FDOQ5739265
Authors: Yifan Zhang, Lorenzo Trippa, Giovanni Parmigiani 
Publication date: 15 July 2016
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://biostats.bepress.com/cgi/viewcontent.cgi?article=1192&context=harvardbiostat
Recommendations
- Adaptive clinical trial designs to detect interaction between treatment and a dichotomous biomarker
- Biomarker-driven adaptive design
- A signature enrichment design with Bayesian adaptive randomization
- Bayesian Response-Adaptive Designs for Basket Trials
- Some optimal adaptive designs in clinical trials
Applications of statistics to biology and medical sciences; meta analysis (62P10) Dynamic programming (90C39)
Cites Work
Cited In (10)
- A signature enrichment design with Bayesian adaptive randomization
- Biomarker-driven adaptive design
- Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects
- Bayesian uncertainty directed trial designs
- Frequentist operating characteristics of Bayesian optimal designs via simulation
- A subgroup cluster-based Bayesian adaptive design for precision medicine
- Adaptive clinical trial designs to detect interaction between treatment and a dichotomous biomarker
- Data-adaptive efficient estimation strategies for biomarker studies embedded in randomized trials
- Design of experiments for a confirmatory trial of precision medicine
- Designing precision medicine trials to yield a greater population impact
This page was built for publication: Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5739265)
